Benlysta (Belimumab) - Important Safety Information from GlaxoSmithKline Pharmaceuticals as approved by the HPRA

Notice type: 3rd Party Publications

Date: 02/04/2019

 

Problem Or Issue:

Important Safety Information communication from GlaxoSmithKline Pharmaceuticals on Increased risk of serious psychiatric events (depression, suicidal ideation or behaviour, or self-injury)

Important Safety Information - Benlysta▼ (Belimumab)

 




« Back